IDEAYA Biosciences Inc IDYA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma
-
IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024
-
IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel
-
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
-
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $30.50
- Day Range
- $30.30–31.21
- 52-Week Range
- $23.41–47.74
- Bid/Ask
- $30.80 / $30.79
- Market Cap
- $2.60 Bil
- Volume/Avg
- 721,174 / 890,322
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 179.29
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 124
- Website
- https://www.ideayabio.com
Comparables
Valuation
|
Metric
|
IDYA
|
LYEL
|
CCCC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.52 | 0.68 | 1.64 |
Price/Sales | 179.29 | 7,089.20 | 11.91 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IDYA
|
LYEL
|
CCCC
|
|---|---|---|---|
Quick Ratio | 17.22 | 15.90 | 4.89 |
Current Ratio | 17.50 | 16.19 | 5.09 |
Interest Coverage | — | — | −715.67 |
Quick Ratio
IDYA
LYEL
CCCC
Profitability
|
Metric
|
IDYA
|
LYEL
|
CCCC
|
|---|---|---|---|
Return on Assets (Normalized) | −17.50% | −21.42% | −22.53% |
Return on Equity (Normalized) | −18.24% | −24.51% | −34.97% |
Return on Invested Capital (Normalized) | −23.54% | −26.29% | −30.08% |
Return on Assets
IDYA
LYEL
CCCC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Bxrcgbzs | Dklh | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tcjfzfc | Myxyyhx | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Yssmbvy | Kgjxdx | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Svsvjxjqh | Fqnbwy | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Mqntpldqr | Jypp | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Hwcrwvjrr | Cjv | $28.1 Bil | |||
| Moderna Inc
MRNA
| Bvvxpgv | Gdw | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Fnwvgzn | Qswdz | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Rnfspfkh | Ddnhcv | $13.4 Bil | |||
| Incyte Corp
INCY
| Zfwftxrz | Bjksm | $12.7 Bil |
United States